Raising Funds For MS Research One Party At A Time, Canada
Medical News Today (press release) - UK
They'll be joined by others around the world hosting parties in support of research to end multiple sclerosis. "We believe that the MS Global Dinner Party ...
See all stories on this topic

ZymoGenetics, Inc. Q4 2007 Earnings Call Transcript
Seeking Alpha - New York,NY,USA
We also expect to begin two multiple sclerosis studies in the early part of this year. One is the Phase 2 study in relapsing-remitting disease and the other ...
See all stories on this topic

Active Biotech Year-End Report January-December 2007
PharmaLive.com (press release) - Newtown,PA,USA
Comments from President and CEO Sven Andréasson: "During the year, the US and European regulatory authorities approved laquinimod for Phase III and ...
See all stories on this topic

Experimental MS drug shows promise, offers new window on disease
Science Centric - Sofia,Sofia Town,Bulgaria
The study, reported in the 14 February 2008 issue of the 'New England Journal of Medicine,' showed that the drug, rituximab, dramatically reduced the number ...
See all stories on this topic

Cancer drug slows multiple sclerosis
Reuters via Yahoo! News Thu, 14 Feb 2008 12:26 PM PST
Two infusions of the cancer drug Rituxan given 2 weeks apart slowed the progression of multiple sclerosis for nearly 1 year, researchers reported on Wednesday.

CORRECTION: Cancer drug slows multiple sclerosis progression Reuters via Yahoo! News Wed, 13 Feb 2008 7:28 PM PST Two infusions of the cancer drug Rituxan given two weeks apart slowed the progression of multiple sclerosis for nearly a year, researchers reported on Wednesday.

Drug that targets different part of immune system may help multiple sclerosis patients Minneapolis-St. Paul Star Tribune Wed, 13 Feb 2008 6:24 PM PST An experimental treatment for multiple sclerosis that targets a portion of the immune system not previously subjected to therapy reduced damaging lesions of the nervous system by 91 percent and relapses of the disease by 58 percent, researchers reported today in the New England Journal of Medicine.

Marijuana slows thinking in MS patients UPI Thu, 14 Feb 2008 3:55 PM PST Smoking marijuana may make cognitive and emotional problems worse in multiple sclerosis patients, a Canadian study finds.

MS therapy shows promise in test Los Angeles Times Thu, 14 Feb 2008 0:16 AM PST A cancer drug greatly reduces brain lesions and relapses in patients with the most common form of the disabling disease. An experimental treatment for multiple sclerosis that targets a portion of the immune system not previously subjected to therapy reduced damaging lesions of the nervous system by 91% and relapses of the disease by 58%, researchers report today.

Pot may impair mental function in MS patients CTV.ca Thu, 14 Feb 2008 5:22 AM PST Patients with multiple sclerosis who choose to smoke marijuana to help relieve some of their symptoms may be harming their cognitive abilities, finds new Canadian research.

Smoking pot may slow MS sufferers' thoughts New Scientist Thu, 14 Feb 2008 3:12 AM PST People with multiple sclerosis who smoke marijuana may process thoughts more slowly than people with MS who do not, hints a preliminary study

Promising Experimental MS Drug Offers New Window On Disease Medical News Today Thu, 14 Feb 2008 5:17 AM PST A drug therapy currently used to treat non-Hodgkin's lymphoma and rheumatoid arthritis had a significant effect in treating the most common form of multiple sclerosis in a small, short-term clinical trial.

Smoking Marijuana Impairs Cognitive Function In MS Patients Medical News Today Thu, 14 Feb 2008 1:15 AM PST People with multiple sclerosis (MS) who smoke marijuana are more likely to have emotional and memory problems, according to research published February 13, 2008, in the online edition of Neurology®, the medical journal of the American Academy of Neurology.

Lawyer argues killer's health at risk if jailed
ABC via Yahoo!7 News Wed, 13 Feb 2008 8:13 PM PST
A Supreme Court judge is being urged not to jail a young man who has been convicted of manslaughter, with lawyers arguing it could worsen his multiple sclerosis.

Wednesday's Winners & Losers: Nortel Networks
TheStreet.com - USA
Acorda will use the proceeds to finish its second late-stage clinical trial on multiple sclerosis treatment Fampridine-SR and for a regulatory filing and ...
See all stories on this topic

Wednesday's Health Winners & Losers
TheStreet.com - USA
Acorda will use the proceeds to finish its second late-stage clinical trial on multiple sclerosis treatment Fampridine-SR and for a regulatory filing and ...
See all stories on this topic

Acorda Therapeutics Q4 Loss Widens On Expenses [ACOR]
RTT News - Williamsville,NY,USA
We also initiated investments for the commercialization of Fampridine-SR, if approved.” As of December 31, 2007, Acorda held cash, cash equivalents and ...
See all stories on this topic

Genentech, Biogen's Rituxan Cuts Relapses of Multiple Sclerosis
Bloomberg - USA
s Campath has shown a similar effect in clinical trials, he said. ``The real strength is the magnitude of effect on the MRI, the relapse rate, ...
See all stories on this topic

Genzyme Delivers Strong Fourth Quarter to Conclude Outstanding Year
PR Newswire (press release) - New York,NY,USA
Genzyme(R), Myozyme(R), Fabrazyme(R), Cerezyme(R), Renagel(R), Renvela(R), Thymoglobulin(R), Synvisc(R), Campath(R) and Clolar(R) are registered trademarks ...
See all stories on this topic